NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement…
Ness-Ziona, Israel, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy…
First patient dosed in Phase 1/2a study with novel immune rejuvenator, a trispecific antibody-fusion protein Two MDX2004 abstracts accepted for…
MAINZ, Germany, October 28, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), will host an edition of…
Ongoing Phase II Clinical Trials, Recently Issued Patents, and AI Integration Initiatives Set the Stage for Continuing Progress in 2026PHOENIX, Oct.…
Ongoing Phase II Clinical Trials, Recently Issued Patents, and AI Integration Initiatives Set the Stage for Continuing Progress in 2026PHOENIX, Oct.…
Ongoing Phase II Clinical Trials, Recently Issued Patents, and AI Integration Initiatives Set the Stage for Continuing Progress in 2026PHOENIX, Oct.…
Dr Tayton-Martin brings broad experience of biotech company building, fund-raising, M&A, business development and operations with a strong track record…
Dr Tayton-Martin brings broad experience of biotech company building, fund-raising, M&A, business development and operations with a strong track record…
Dr Tayton-Martin brings broad experience of biotech company building, fund-raising, M&A, business development and operations with a strong track record…